Rhumbline Advisers Immunic, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.13 - $12.25 $69,241 - $270,994	-22,122 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$9.54 - $14.26 $49,436 - $73,895	5,182 Added 30.59%	22,122 $250,000
Q4 2021 Feb 10, 2022	BUY	$7.34 - $10.25 $11,861 - $16,564	1,616 Added 10.55%	16,940 $162,000
Q3 2021 Nov 12, 2021	BUY	$8.05 - $13.29 $9,378 - $15,482	1,165 Added 8.23%	15,324 $136,000
Q2 2021 Aug 05, 2021	BUY	$11.76 - $16.85 $166,509 - $238,579	14,159 New	14,159 $174,000

57.6M

600

254K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $35.1M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.